Inventor · disambiguated record
Zhihua Qiu
Also filed as: QIU ZHIHUA
6 granted patents·3 pending applications·84 citations·filing 1998–2021
82Inventor score
Files withUNIVERA PHARM INC4QYUNS THERAPEUTICS CO LTD2JIANGSU QYUNS THERAPEUTICS CO LTD1UNIGEN PHARMACEUTICALS INC1
Top patents by PatentIndex Score
9 records- 0173US6210680B1Method for the prevention and treatment of chronic venous insufficiencyUNIVERA PHARM INC·Filed 1999·Granted Apr 3, 2001·38 cites·11 claims
- 0273US6133440AProcess for the preparation of immunomodulatory polysaccharides from aloeUNIVERA PHARM INC·Filed 1998·Granted Oct 17, 2000·30 cites·4 claims
- 0353US2024254244A1ANTI-HUMAN INTERFERON a RECEPTOR 1 MONOCLONAL ANTIBODY AND APPLICATION THEREOFQYUNS THERAPEUTICS CO LTD·Filed 2021·Application pending·0 cites
- 0451US6436679B1Process for the preparation of immunodulatory polysaccharides from aloeUNIGEN PHARMACEUTICALS INC·Filed 1999·Granted Aug 20, 2002·8 cites·10 claims
- 0551US6271214B1Process for the preparation of immunomodulatory polysaccharides from aloeUNIVERA PHARM INC·Filed 1999·Granted Aug 7, 2001·8 cites·2 claims
- 0647US2001000731A1Method for the prevention and treatment of chronic venous insufficiencyFiled 2000·Application pending·0 cites
- 0746US12297280B2Monoclonal antibodies against human interleukin-4 receptor alpha, encoding nucleic acids thereof and method of use thereof to treat IL-4 or IL-4/IL-13-mediated diseasesQYUNS THERAPEUTICS CO LTD·Filed 2019·Granted May 13, 2025·0 cites·14 claims
- 0842US2003096378A1Process for the preparation of immunomodulatory polysaccharides from aloeUNIVERA PHARM INC·Filed 2002·Application pending·0 cites
- 0938US12110323B2Anti-human interleukin 17A monoclonal antibody and application thereofJIANGSU QYUNS THERAPEUTICS CO LTD·Filed 2018·Granted Oct 8, 2024·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Zhihua Qiu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →